About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

88.65 -3.58 (-3.88%)
Streaming Delayed Price Updated: 10:15 AM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
From Guardant Health, Inc.
Via Business Wire
News headline image
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 
Via StockStory
Topics Economy Stocks
News headline image
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗
Via Chartmill
News headline image
The Great Rotation: Small-Caps Break Record Highs as the 'Catch-Up' Trade Ignites
In a dramatic shift that has caught Wall Street’s heavy hitters off guard, the Russell 2000 index has surged to unprecedented heights in early 2026, signaling the definitive arrival of the long-awaited... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
Via StockStory
Topics Economy Government World Trade
News headline image
Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales
Diagnostics company Guardant Health (NASDAQ:GH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 39.4% year on year to $281.3 million. The company’s full-year revenue... 
Via StockStory
News headline image
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
From Guardant Health, Inc.
Via Business Wire
News headline image
Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Unpopular Stocks We Think Twice About
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
Should You Buy Guardant Health Before Feb. 19? ↗
This genomics stock appears to be at an inflection point. 
Via The Motley Fool
Topics Earnings
News headline image
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers. 
Via StockStory
News headline image
CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside
Via AB Newswire
Topics Intellectual Property
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
From Guardant Health, Inc.
Via Business Wire
News headline image
BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era
As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
1 Growth Stock Set to Flourishand 2 We Avoid
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.